Insider · CIK 0001988551
Hyun W. Bae
Files at KAPA (Kairos Pharma, LTD.). First filing -, latest -.
In brief
Hyun W. Bae files SEC Form 4 as director at KAPA (Kairos Pharma, LTD.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Hyun W. Bae has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 16, 2025 | KAPA Kairos Pharma, LTD. | AGrant or award COMMON STOCK | +10,000 | $0.00 | $0 | 54,286 | Dec 23, 2025 |
| Oct 8, 2025 | KAPA Kairos Pharma, LTD. | AGrant or award COMMON STOCK | +19,084 | $0.00 | $0 | 73,370 | Dec 23, 2025 |
Questions about Hyun W. Bae
Answered from the filings on this page, as of the latest one.
Is Hyun W. Bae buying or selling?
Hyun W. Bae has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Hyun W. Bae's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Hyun W. Bae has 0.
Where does Hyun W. Bae file Form 4?
Hyun W. Bae has filed Form 4 at KAPA (Kairos Pharma, LTD.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.